BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Mallinckrodt deal signals turnaround for Silence at potential $693M per target
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Mallinckrodt deal signals turnaround for Silence at potential $693M per target
July 22, 2019
By
Nuala Moran
No Comments
LONDON – Silence Therapeutics plc has finally secured a deal to transform its fortunes, signing up Mallinckrodt plc in a potential $693 million-per-asset collaboration to develop siRNA therapeutics that block the complement inflammatory cascade.
BioWorld
Deals and M&A
Collaboration
Inflammatory